Aug 13, 2020
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Jun 16, 2020
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
Jun 12, 2020
Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed Acute Myeloid Leukemia at Virtual EHA Annual Congress 2020
May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
May 11, 2020
AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patients
May 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta(TM) for metastatic non-small cell lung cancer with METex14
Apr 28, 2020
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight
Apr 16, 2020
Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment
Mar 31, 2020
Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy
Mar 26, 2020
Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia
Mar 16, 2020
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
Jan 15, 2020
Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy
Jan 02, 2020
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
Dec 20, 2019
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
Dec 09, 2019
BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019
Nov 20, 2019
Biovica's DiviTum Validated as a Dynamic Biomarker in Metastatic Breast Cancer in Collaboration With Institut Curie, Paris
Nov 19, 2019
BerGenBio ASA: Results for the Third Quarter 2019
Nov 08, 2019
BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA®
Nov 06, 2019
BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®
Oct 23, 2019
Women living with metastatic breast cancer in British Columbia now have public access to KISQALI®